


# WM8 Bioinformatics

Analyses and interpretation of DNA variants

Hubert Hackl

# Analyses and interpretation of DNA variants



# Definitions

**Mutation:** any changes (physical events) made in the sequence of DNA also called variants

**Point mutation:** any changes made to a single nucleotide in the DNA sequence also called single nucleotide variant (SNV)

**Single-nucleotide polymorphism (SNP):** mutations or variants in context of a population (previously an arbitrary cutoff of >1% was used)

**Indel:** short (only a few bases) insertion or deletion in the DNA sequence

**Structural DNA variation:** long insertions deletion translocations of the DNA (genome, chromosomes)

**Fusion gene:** a hybrid gene formed from two previously separate genes as a result of translocation in the cancer genome (e.g. BCR-ABL in leukemia).

# Definitions

**Non-synonymous mutation:** amino acid sequence of protein is altered

**Synonymous mutation:** amino acid sequence of protein is not altered

**Functional variant:** affects the molecular function of a protein (as a gain, loss or switch of function).


**Nonfunctional variant:** not appreciably affect the molecular function of a protein.

**Driver variant:** selective advantage to a particular tumor cell, i.e. often mutations in oncogenes or tumor suppressor genes


**Passenger variant:** no selective advantage

*A substitution might dramatically affect the function of a protein **without** providing any selective advantage to the tumor (it is a functional passenger variant).*

# Somatic mutation detection in tumor samples





# Intratumor heterogeneity and clonal evolution



# Intratumor heterogeneity and clonal evolution

Clonal Theory (Nowell 1976)



Number of chromosomes in a cell

**Diploid:** proportion of cancer cells have the same number of chromosomes as normal, healthy cells (2 sets 23 each)

**Aneuploid:** too many or too few chromosomes, cancer may be more aggressive

**Tumor purity:** percentage of all cancer cells in tumor sample

**Variant allele fraction:** Fraction of alleles (DNA molecules) from a locus that carry a mutation (also the expected fraction of supporting reads)

**Variant allele frequency:** Frequency of variant allele in population

**Clonal:** all cells in a tumor sample have a specific mutation


**Subclonal:** only a subgroup of all cells in a tumor sample have a specific mutation

**Cancer cell fraction:** fraction of cancer cells with mutation



# Depth of coverage

Depth of coverage affects the accuracy of allelic fraction estimates



Sample *purity* and *local copy number* information are integrated with allelic fractions

Normal cells




Cancer cells





Example:  
Tumor purity = 67%  
Absolute copy number in tumor = 3



Resulting *cancer cell fraction* as probability distribution





# Clonal-subclonal variants; Cancer cell fraction (CCF)



# Patterns of clonal evolution



# Example: Targeted exome sequencing in DBLCL



# Databases for variants/mutations/SNPs

dbSNP

The Human Genome Mutation Database (HGMD)

OMIM

SNPedia

1000 Genomes

HapMap

GnomAD

Specific for cancer:

Catalogue of Somatic Mutations in Cancer (COSMIC)


IntOGen

cBioPortal


# Clinical Interpretation of Variants in Cancer

BaseSpace Knowledge Network  
Cancer Driver Log (CanDL)  
Cancer Genome Interpreter  
Clinical Interpretation of Variants in Cancer (CIViC)  
ClinVar  
COSMIC Drug Resistance Curation  
Database of Curated Mutations (DoCM)  
Database of evidence for precision oncology (DEPO)  
Gene Drug Knowledge Database  
Genomics of Drug Sensitivity (GDSC)  
HemOnc  
JAX Clinical Knowledgebase  
My Cancer Genome  
OncoKB  
Personalized Cancer Therapy (PCT)  
Pharmacogenomics Knowledgebase (PharmGKB)  
Precision Medicine Knowledgebase (PMKB)  
Therapeutic target database  
Variant Interpretation for Cancer Consortium (VICC)

# Long tail distribution of cancer genes



# Identifying driver mutations





# Map mutations to functional genomic features and annotation

Oncotator (Funcotator)

Ensembl Variant Effect Predictor (VEP)

ANNOVAR

snpEff

GPViz (visualization)

# Oncotator

## What is Oncotator?

Oncotator is a web application for annotating human genomic point mutations and indels with data relevant to cancer researchers. Annotations are aggregated from the following resources:

### Genomic Annotations

- Gene, transcript, and functional consequence annotations using [GENCODE](#) for hg19.
- Reference sequence around a variant.
- GC content around a variant.
- Human DNA Repair Gene annotations from [Wood et al.](#)

### Protein Annotations

- Site-specific protein annotations from [UniProt](#).
- Functional impact predictions from [dbNSFP](#).

### Cancer Variant Annotations

- Observed cancer mutation frequency annotations from [COSMIC](#).
- Cancer gene and mutation annotations from the [Cancer GenCensus](#).
- Overlapping mutations from the [Cancer Cell Line Encyclopedia](#).
- Cancer gene annotations from the [Familial Cancer Database](#).
- Cancer variant annotations from [ClinVar](#).

### Non-Cancer Variant Annotations

- Common SNP annotations from [dbSNP](#).
- Variant annotations from [1000 Genomes](#).
- Variant annotations from [NHLBI GO Exome Sequencing Project \(ESP\)](#).

<http://www.broadinstitute.org/oncotator/>



# Ensembl Variant Effect Predictor (VEP)

## Variant Effect Predictor results

[Job details](#)

[Summary statistics](#)

Category	Count
Variants processed	544
Variants filtered out	0
Novel / existing variants	476 (87.5) / 68 (12.5)
Overlapped genes	60
Overlapped transcripts	240
Overlapped regulatory features	20



## Survey for VEP users

We are interested to hear your thoughts on VEP, and would like to invite you to participate in our survey. Your response is greatly appreciated and will help us guide the future development of VEP.

If you would like to help, please [click to take the survey now](#).

## Results preview

[Navigation](#)

[Filters](#)

[Download](#)

Page: 1 of 11 | Show: 1 5 10 50 All variants

Uploaded variant is defined Add


All: [VCF](#) [VEP](#) [TXT](#)

BioMart: [Variants](#) [Genes](#)

Show/hide columns (31 hidden)																					
Uploaded variant	Location	Allele	Consequence	Impact	Symbol	Gene	Feature type	Feature	Biotype	Exon	Intron	cDNA position	CDS position	Protein position	Amino acids	Codons	Existing variant	Distance to transcript	HGNC ID	SIFT	PolyPhen
-	<a href="#">10.89717675-89717675</a>	G	<span>missense_variant</span>	MODERATE	PTEN	<a href="#">5728</a>	Transcript	NM_000314.4	protein_coding	7/9	-	1732	700	234	R/G	CGG/GGG	<a href="#">COSM4167544</a> <a href="#">COSM5118</a>	-	-	0.12	0.069
-	<a href="#">1.115256563-115256563</a>	C	<span>missense_variant</span>	MODERATE	NRAS	<a href="#">4893</a>	Transcript	NM_002524.4	protein_coding	3/7	-	402	148	50	T/A	ACC/GCC	-	-	-	0.22	0.842
-	<a href="#">1.43815008-43815009</a>	-	<span>frameshift_variant</span>	HIGH	MPL	<a href="#">4352</a>	Transcript	NM_005373.2	protein_coding	10/12	-	1589	1544	515	W/X	TGG/TG	<a href="#">COSM142839</a> <a href="#">COSM18918</a> <a href="#">COSM3719407</a>	-	-	-	-
-	<a href="#">1.43815008-43815009</a>	-	<span>frameshift_variant</span>	HIGH	MPL	<a href="#">4352</a>	Transcript	XM_005270874.1	protein_coding	10/12	-	1523	1523	508	W/X	TGG/TG	<a href="#">COSM142839</a> <a href="#">COSM18918</a> <a href="#">COSM3719407</a>	-	-	-	-
-	<a href="#">1.43815008-43815009</a>	-	<span>regulatory_region_variant</span>	MODIFIER	-	-	RegulatoryFeature	<a href="#">ENSR00000007255</a>	promoter_flanking_region	-	-	-	-	-	-	-	<a href="#">COSM142839</a> <a href="#">COSM18918</a> <a href="#">COSM3719407</a>	-	-	-	-
-	<a href="#">10.89717769-89717770</a>	-	<span>frameshift_variant</span>	HIGH	PTEN	<a href="#">5728</a>	Transcript	NM_000314.4	protein_coding	7/9	-	1827	795	265	L/X	CTA/CT	<a href="#">COSM30622</a>	-	-	-	-
-	<a href="#">10.89685270-89685271</a>	-	<span>frameshift_variant</span> <span>splice_region_variant</span>	HIGH	PTEN	<a href="#">5728</a>	Transcript	NM_000314.4	protein_coding	3/9	-	1198	166	56	F/X	TTT/TT	<a href="#">COSM5257</a>	-	-	-	-
-	<a href="#">10.89720898-89720899</a>	-	<span>intron_variant</span>	MODIFIER	PTEN	<a href="#">5728</a>	Transcript	NM_000314.4	protein_coding	-	8/8	-	-	-	-	-	<a href="#">COSM5913</a>	-	-	-	-

[http://grch37.ensembl.org/Homo\\_sapiens/Tools/VEP](http://grch37.ensembl.org/Homo_sapiens/Tools/VEP)

# GPViz



<http://icbi.at/software/gpviz/gpviz.shtml>

Snajder et al, Bioinformatics 2013

Effect on the function of a protein or regulatory element (functional impact)

SIFT

PolyPhen2

CADD

CHASM/VEST

TransFIC



PredictSNP

MutationAssessor

# MutationAssessor

Chr Pos RefAlt AltAll

Mutation	AA variant	Gene	MSA	PDB	Func. Impact	FI score	Uniprot	Refseq	MSA height
2,212288939,C,G	G936A	ERBB4	msa	pdb	medium	2.4	ERBB4_HUMAN	XP_005246432	1684



# Mutation3D

## mutation3D

[Home](#) [Advanced](#) [About](#)


Isocitrate dehydrogenase  
[NADP] cytoplasmic

### Protein Data

UniProt ID [O75874](#)  
Gene IDH1  
Length 414  
Mutations 1  
Clusters 0  
Models 11

### Links

[Clustering Data File](#)  
[PyMOL Session File](#)  
[Permalink](#)



View: [Cartoon](#) [Line](#) [Ribbon](#)


### Model Information

Model: [1T09\\_A\\_1\\_414](#)  
Source: PDB

AA Range	1-414
Source PDB	1T09
Coverage	100.00%
Seq. Identity	100%

### Cluster Selection


No clusters were found for this model.



[Hide Domains](#)

[Select Model](#)

# Effects on molecular interactions (edgetic mutations)



Yi et al. Nature Rev Genet. 2017



Detect mutations, genes and pathways recurrently altered or with overrepresentation of functional mutations

MutSig, MutSigCV

OncodriveFM


ActiveDriver

MuSIC

Mutually Exclusive Modules in cancer (MEMo)

HotNet


# MutSig (MutSigCV)




**MutSig** builds a model of the background mutation processes (BMR) that were at work during formation of the tumors, and it analyzes the mutations of each gene to identify genes that were mutated more often than expected by chance, given the background model.

**MutSigCV** (CV for 'covariate') improves the BMR estimation by pooling data from 'neighbor' genes with similar genomic properties such as DNA replication time, chromatin state (open/closed), and general level of transcription activity.

# Antigen prediction (cancer immunity cycle)



# Antigen prediction



In human MHC is called HLA

Somatic mutation in tumor → Peptide (length 8-11)

HLA-type

Peptide

NetMHCpan

→ epitope?

<http://www.cbs.dtu.dk/services/NetMHCpan/>

# Predictive marker


A **predictive marker** is a particular protein or gene that indicates sensitivity or resistance to a specific therapy.

The use of predictive markers is becoming increasingly relevant in cancer therapy as it allows for better identification of patients who will respond positively to the therapy.

Expression of estrogen and progesterone receptors can determine the benefits of hormone therapy, whilst the benefit of treating breast cancer patients with herceptin (Trastuzumab) is determined by the expression of HER2.

# Predictive marker

Variants (mutations) might also be used as predictive marker e.g. BRAF V600E mutations in melanoma:




# Example: EDN1-variant as predictive marker for therapy with Bevacizumab in metastatic breast cancer

Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer.

Genotype of 10 SNPs associated with VEGF and hypertension tested

Genotype					Bevacizumab cohort			
SNP	GENE	wt (+/+)	+/-	-/-	wt (+/+)	+/-	-/-	P*
rs13207351	VEGF-152 G/A	GG	GA	AA	92	63	8	0.62
rs2010963	VEGF-634 G/C	GG	GC	CC	13	85	65	0.055
rs3025039	VEGF-936 C/T	CC	CT	TT	113	41	7	0.30
rs1570360	VEGF-1154 G/A	GG	GA	AA	31	36	54	4.8x10 <sup>-5</sup>
rs833061	VEGF-1498 C/T	CC	CT	TT	35	89	39	0.29
rs699947	VEGF-2578 C/A	AA	CA	CC	33	89	41	0.28
rs9582036	VEGFR-1 C/A	CC	CA	AA	81	80	2	5.7x10 <sup>-4</sup>
rs13333226	UMOD A/G	GG	AG	AA	109	49	5	0.94
rs3754777	STK39 A/G	GG	AG	AA	121	37	5	0.45
rs5370	EDN1 G/T	GG	GT	TT	108	48	7	0.73
					Control cohort			
rs-5370	EDN1 G/T	GG	GT	TT	67	32	6	0.56
* Deviation from Hardy-Weinberg equilibrium (HWE)								

# Example: EDN1-variant as predictive marker



This is a germline mutation, so can tested in blood!